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1. Traditional biotechnology, achieving genetic modification by such 
techniques as hybridization and selective breeding, has always played an 
essential role in the development and improvement of plants, animals and 
in manufacturing processes.. Within the last decade ne~ techniques of 
genetic modification have been developed to make possible major advances 
in animal and plant breeding, and in the modi'fication and the use of 
microorganisms and cell lines to manufacture medicines, fine chemicals, 
and many other products. These new techniques, such as recombinant DNA or 
RNA, and cell fusion, are now generally known as genetic engineering. 
2. The question has been posed as to whether these newer genetic modification 
techniques bring with them extra or new risks for consumer/worker health 
and safety or the environment. In that they enable much more precise 
genetic modification, there is no.! priori reason to believe that their 
use in enclosed manufacturing processes entails any extra or new risks .. 
Nevertheless, the use of genetically engineered organisms in both 
laboratory and industrial conditions has been subject to regulatory 
oversight in the Community and in the U.S. Moreover, in recent years, the 
planned release of genetically engineered organisms in agricultural and 
environmental applications has given rise to futher debate about the 
possible risks involved. 
3. Several countries have therefore been reviewing existing regulations, and 
generally assessing the risks to human and environmental safety from 
genetic engineering. A major study-report prepared by leading 
international experts for the OECD entitled "Recombinant DNA Safety 
Considerations" has been recently published. 
The report distinguishes between - the use of geneti ea lly engineered 
organisms in enclosed manufacturing 
systems, and the products produced 
by such methods, 
and 
- the planned release of genetically 
engineered organisms in 
agri cultural and environmental 
applications. 
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4.. The report concludes that genetically engineered organisms used in 
manufacturing systems contained or enclosed to the appropriate standard.s 
and not at any stage unappropri ate Ly exposed to or re leased into the 
environment... give rise to no new or additional risks, either for the 
workers involved, the environment or in respect of the resultant productsa 
It states that, for the majority of cases..,. the levels of physical and 
biological containment laid down by the principles of Good Industrial 
Large-Scale Production CGILSP) would provide adequate s~feguards for 
worker and environmental protectionc In those few cases where higher risk 
organisms have to be used (e.g. vaccines) well-known containment measures 
would be applied in addition to GILSP. 
5.. On the question of planned release of genet i ea Lly engineered organisms in 
agri cultural and environmental applications, the report concludes that 
while risks exist, they can be assessed to some extent by analogy with 
information about existing organisms. However, there is insufficient 
experience at this stage to lay down a coherent set of regulations. 
Instead the report recommends a prior case-by-case evaluation of all 
planned release applicationss 
6s The Community took a first step in biotechnology regulation in 1982 with 
the adoption of a Council Recommendation on laboratory safety measures in 
relation to rDNA experimentation.. A new coordination procedure for 
Community evaluation of biotech medicines was proposed in October 1984 and 
is currently before Council" Existing Community legislation already 
covers the protection of workers from the risks related to exposure to 
biological agents at work, and work is L. ..,..-ogress on specific norms for 
pathogenic biological agents. In July 1985, the Biotechnology Regulation 
lnterservice Committee (BRIC) was set up, and has been ass~~sing the need 
for Commu,ity regulation in this area. Existing Community legislation in 
respect of products, worker protection and environmental protection is 
being re-evaluated as to its adequacym BRIC was involved in the 
preparation of the OECD report referred to ~bovep and organized on 29-30 
April 1986 a high-level meeting with Member States officials to discuss 
the regulation of biotechnology in the Community, taking ~ccount inter 
alia the OECD report~ Following this meeting, Member State officials have 
been requested to keep the Commission services informed of national 
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activities and intentions in regard to biotechnology regulation.. The 
Commission services involved have also been in consultation with the 
industries most involved with modern biotechnology - indeed the chemical, 
agrochemical, pharmaceutical and food industries have submitted a joint 
report to the Commission.1' setting out their views on the need for 
Community-wide regulation of biotechnology., At the same time, Community 
research is being undertaken in the framework of the Biotechnology 
Research Action Programme to develop further the scientific basis for the 
.assessment of risks resulting from the release (accidental or deliberate) 
of genetically engineered organisms. Member State representatives on the 
Advisory Committee C11 CGC 11 ) for the Biotechnology Research Action Programme 
have been requested to prepare a summary of relevant research in national 
programmes. 
7. In the light of the examination which has been undertaken by the services, 
the Commission believes the rapid elabor!'ti on of a Community framework of 
biotechnology regulation to be of crucial importance to the 
industrialization of this new technology in the Community. Equally, 
citizens, industrial· workers, and the environment, need to be provided 
with adequate protection throughout the Community from any potential 
hazards arising from the applications of these technologies. The internal 
market arguments for Community-wide regulation of biotechnology are clear. 
Microorganisms are no respecters of national frontiers, and nothing short 
of Commu,ity-wide regulation can offer the necessary co~sumer and 
environmental protection. 
8. The Commission therefore intends to introduce proposals for Community 
regulation of biotechnology by Summer 1987 with a view to providing a high 
and common level of human and environmental protection throughout the 
Community, and so as to prevent market fragmentation by separate 
unilateral actions by Member States. The Commission's proposals will 
address two distinct aspects of the use of genetic engineering, viz: 
A. Levels of physical and biological containment, accident control, and 
waste management in industrial applications, 
and, 
B. Authorization of planned re lease of geneti ea l ly engineered organisms 
into the environment. 
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9. The purpose of the first proposals CA) would be to ensure adequate 
Community-wide levels of containment, accident procedures and waste 
management in respect of the use of geneti cal Ly engineered organ isms in 
enclosed manufacturing systems. This measure would ensure adequate 
standards, while at the same time comparable conditions of industrial 
production as between Member States. It will be based on usual 
requirements of good manufacturing practice = and may in its scope cover 
other biological agents used in industry. 
10. Because international experience of risk assessment in the field of 
"planned re lease" is sti Ll limited, it is not possible to propose any 
general guidelines or testing requirements for the time being. The 
Commission will be proposing a Community case-by-case evaluation and 
authorization procedure based on mandatory phased notification by 
industry.. This is in tine with industry's own proposals and with the 
recommendation of the OECD report.. The stages at which Community 
notification would be mandatory,, the proc.edures for dealing with 
agricultural and environmental applications, and the general question of a 
priori exemptions, have yet to be agreed and wi L l be a matter for further 
discussion with experts and with Member States officials in the light of 
the reevaluation of existing Community legislation referred to in para 6. 
11.. These new technologies have a significant international impact and the 
market for the new biotechnology is ltfoddwide., The Commission therefore 
considers it to be of importance that ·:n the elaboration of Community 
regulations care is taken to achieve and maintain a broad measure of 
harmo·nizati on with other countries, in particular with the practices of 
our principal trade partners.. The Co•ission is prepared to sponsor or 
co-sponsor general and technical international meetings on aspects of the 
regulation of genetically engineered organisms .. 
12. The Commission is convinced that the development of a Community regulatory 
framework, which will both provide a clear~ rational and evolving basis 
for the development of biotechnology and also ensure adequate protection 
of human health and the environment is an urgent necessity.. To this end 
the Commission services, working together in the framework of BRIC, are 
Launching the necessary work to draft proposals for legislation on 
genet ica Uy ~ngineer~d orgM isms to be presented to the Council by Summer 
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1987. In the meantime, the Member States are requested to inform the 
Commission of their activities and intentions in the fields of 
biotechnology regulation and risk assessment research. 
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